PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-3.66%
Negative net income growth while AXSM stands at 81.68%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
13.04%
Some D&A expansion while AXSM is negative at -2.02%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Deferred tax of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
1.43%
Less SBC growth vs. AXSM's 20.19%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-401.62%
Both reduce yoy usage, with AXSM at -157.65%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both negative yoy AP, with AXSM at -111.01%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-97.99%
Both reduce yoy usage, with AXSM at -63.31%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-100.00%
Both negative yoy, with AXSM at -97.50%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-93.84%
Negative yoy CFO while AXSM is 78.88%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-375.00%
Negative yoy CapEx while AXSM is 60.74%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-375.00%
We reduce yoy invests while AXSM stands at 60.74%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-84.27%
Both yoy lines negative, with AXSM at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.